Clinical Trials Logo

Human Papillomavirus Type 16 clinical trials

View clinical trials related to Human Papillomavirus Type 16.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04131413 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia, Grade III

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Start date: September 14, 2020
Phase: Phase 1
Study type: Interventional

The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.